Drugs / MC0518
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT06075706 | Nov 2023 → Feb 2026 overdue | acute graft versus host disease | medac GmbH | Active not recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT04629833 | Aug 2021 → Aug 2027 expected | acute graft versus host disease | medac GmbH | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MC0518 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04629833 ↗ |
| Modality | Cell therapy | “Mesenchymal Stromal Cells MC0518” NCT04629833 ↗ |
| Route | Intravenous | “MC0518 will be intravenously infused immediately after thawing.” NCT04629833 ↗ |